Drug intelligence / Profile preview

carfilzomib + cyclophosphamide + dexamethasone + melphalan

Development stage: Unknown
Lead developer: Amgen
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy regimen used in multiple myeloma treatment. It consists of an induction phase with carfilzomib, cyclophosphamide, and dexamethasone (CAR-CY-DEX), followed by a conditioning regimen with carfilzomib and high-dose melphalan before autologous stem cell transplantation (ASCT), and sometimes followed by maintenance therapy with carfilzomib and dexamethasone. This regimen has been studied in both newly diagnosed multiple myeloma patients and for those with relapsed disease requiring salvage therapy.

Brand names: Kyprolis
Other names: CarCyDex + carfilzomib + melphalan

Targets

PSMB8 (Immunoproteasome)PSMB5 (Proteasome subunit beta Type-5)

Beyond the preview

Go deeper on carfilzomib + cyclophosphamide + dexamethasone + melphalan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carfilzomib + cyclophosphamide + dexamethasone + melphalan.

Explore the full profile